share_log
Breakings ·  Oct 17 13:20
Biogen: Eisai to Request Reconsideration of Decision Within 90 Days to Make Lecanemab Available for Eligible People Living With Early Ad in Australia
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment